New England Journal Of Medicine Publishes Data From Pivotal Phase 3 PROVENGE IMPACT Study

29 July 2010, 5:23 am

Dendreon Corporation (Nasdaq: DNDN) announced the publication of data from the pivotal Phase 3 IMPACT study in the New England Journal of Medicine, showing that PROVENGE® (sipuleucel-T) demonstrated a statistically significant improvement in overall survival compared to control in men with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer (mCRPC). The ...... Read More »

More Topics from "Articles"

• London and Birmingham licensing consultation events full up
• Badminton England choose nine-man squad for Paris World Championships
• GOLF NOTES: North Haven's Caggiano wins New England tourney (with tip from a pro)
• Events: Related News
• Events Calendar
• More controversy papal event in England to charge fee
• Pilgrims must pay to attend 2 pope events in UK
• Pilgrims must pay to attend 2 big events in England during pope's visit in September
• Catholics must pay to attend 2 big events in England during pope's visit in September